Unfortunately, ~30–40% of patients with ER+ breast cancer fail to respond (de novo resistance) or become resistant (acquired resistance) to tamoxifen, with a deadly outcome, which presents a major clinical challenge in the treatment of breast cancer [4, 5]. Here, ESR1 is linked to breast carcinoma.